ArticlePloS one2016
Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
To Investigate the Diagnostic Accuracy of Exosomal microRNA in Predicting the Aggressiveness of Prostate Cancer in Chinese Patients
To Evaluate the Performance of a Urine Spermine Measuring Device in Predicting Prostate Biopsy Result
To Investigate the Role of Gut Microbiome in Androgen Deprivation Therapy Related Metabolic Changes in Prostate Cancer Patients
To Identify Potential New Urine Marker Panel for Cancer Screening
Artificial Intelligence (AI)-Assisted Risk-based Prostate Cancer Detection: A Synergy of Novel Biomarkers, Advanced Imaging, and Robotic-assisted Diagnosis
Who cites it
28 citing papers in PubMed, 50 citations in OpenAlex.
- ZDHHC9 and spermine metabolism: a palmitoylation-driven pathway to prostate carcinogenesis.Journal of translational medicine · 2025Article
- Metabolomics-Based Liquid Biopsy for Predicting Clinically Significant Prostate Cancer.Cancers · 2025Review
- Polyamine metabolism in prostate cancer.Current opinion in oncology · 2025Review
- Next-Gen Point-of-Care Tool for Ultra-Sensitive Detection of Urinary Spermine for Prostate Cancer Diagnosis.ACS sensors · 2025Article
- Polyamines: the pivotal amines in influencing the tumor microenvironment.Discover oncology · 2024Review
- Identification and validation of a metabolism-related gene signature for predicting the prognosis of paediatric medulloblastoma.Scientific reports · 2024Article
- Expression of ornithine decarboxylase in peripheral blood mononuclear cells from patients with pancreatic adenocarcinoma: A preliminary report.Biomedical reports · 2024Article
- Metabolic instruction of the graft-versus-leukemia immunity.Frontiers in immunology · 2024Review
- Urine spermine and multiparametric magnetic resonance imaging for prediction of prostate cancer in Japanese men.Prostate international · 2023Article
- Identification of a polyamine-related signature and six novel prognostic biomarkers in oral squamous cell carcinoma.Frontiers in molecular biosciences · 2023Article
- CHRDL1, NEFH, TAGLN and SYNM as novel diagnostic biomarkers of benign prostatic hyperplasia and prostate cancer.Cancer biomarkers : section A of Disease markers · 2023Article
- One-Carbon and Polyamine Metabolism as Cancer Therapy Targets.Biomolecules · 2022Review
- Comprehensive biomarker profiles and chemometric filtering of urinary metabolomics for effective discrimination of prostate carcinoma from benign hyperplasia.Scientific reports · 2022Article
- Review
- The Potential Role of Spermine and Its Acetylated Derivative in Human Malignancies.International journal of molecular sciences · 2022Review
- Beyond liquid biopsy: Toward non-invasive assays for distanced cancer diagnostics in pandemics.Biosensors & bioelectronics · 2022Review
- Optimization of training and measurement protocol for eNose analysis of urine headspace aimed at prostate cancer diagnosis.Scientific reports · 2021Article
- Urine spermine and multivariable Spermine Risk Score predict high-grade prostate cancer.Prostate cancer and prostatic diseases · 2021Article
- The Emerging Clinical Role of Spermine in Prostate Cancer.International journal of molecular sciences · 2021Review
- Advances and Perspectives in Prostate Cancer Biomarker Discovery in the Last 5 Years through Tissue and Urine Metabolomics.Metabolites · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current screening methods towards prostate cancer (PCa) are not without limitations. Research work has been on-going to assess if there are other better tests suitable for primary or secondary screening of PCa to supplement the serum prostate specific antigen (PSA) test, which fails to work accurately in a grey zone of 4-10ng/ml. In this pilot study, the potential roles of urinary polyamines as prostate cancer biomarkers were evaluated. PCa, benign prostatic hyperplasia (BPH) patients and healthy controls (HC) showing PSA>4.0ng/ml were enrolled in the study. Their urine samples were obtained, and the urinary levels of putrescine (Put), spermidine (Spd) and spermine (Spm) were determined by ultra-high performance liquid chromatography coupled with triple quadrupole mass spectrometer (UPLC-MS/MS). Receiver operating characteristics (ROC) curve and Student's t-test were used to evaluate their diagnostic accuracies. Among the three biogenic polyamines, Spm had demonstrated a good diagnostic performance when comparing their levels in PCa patients with BPH patients (1.47 in PCa vs 5.87 in BPH; p<0.0001). Results are in accordance with transrectal ultrasound prostatic biopsy (TRUSPB) results, with an area under curve (AUC) value of 0.83±0.03. Therefore urinary Spm shows potential to serve as a novel PCa diagnostic biomarker, which in turn can help to address the limited sensitivity and specificity problem of serum PSA test.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.